W. Rathmell
Last active: 8/8/2016

Molecularly targeted therapy in renal cell carcinoma.

Rathmell WK, Wright TM, Rini BI
Expert Rev Anticancer Ther. 2005 5 (6): 1031-40

PMID: 16336094 · DOI:10.1586/14737140.5.6.1031

Recent developments in the molecular biology of renal cell carcinoma have identified multiple pathways associated with the development of this cancer. Multiple strategies have been investigated targeting these pathways, with significant clinical benefits shown in early studies. This review aims to overview the findings of recent clinical trials and clarify the development of these compounds for use in renal cell carcinoma. The authors also aim to clarify the molecular pathways implicated in renal cell carcinoma and the clinical results in metastatic renal cell carcinoma with agents targeting these pathways. The relevant literature was reviewed concerning pathways implicated in the pathophysiology of renal cell carcinoma including pathways activated secondary to von Hippel-Lindau gene inactivation and PI-3 kinase/Akt/mammalian target of rapamycin pathway activation. Therapeutic targeting based upon underlying molecular biology in renal cell carcinoma has strong rationale. Substantial clinical activity has been reported with various agents targeting these pathways, most notably with vascular endothelial growth factor-targeted therapy. However, investigation is needed to optimally utilize these agents at the appropriate stage of disease and in the best combinations for maximal clinical benefit.

MeSH Terms (14)

Animals Antineoplastic Agents Carcinoma, Renal Cell Clinical Trials as Topic Disease Models, Animal Humans Kidney Neoplasms Neoplasm Invasiveness Protein Kinases Proto-Oncogene Proteins c-akt TOR Serine-Threonine Kinases Transplantation, Heterologous Vascular Endothelial Growth Factor A Von Hippel-Lindau Tumor Suppressor Protein

Connections (1)

This publication is referenced by other Labnodes entities:

Links